AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

843.542

-12.845-1.50%

Number of Gainers:12

Number of Losers:17

Number of Flat:17

PE:- -

High:856.440

Open:856.387

Low:842.294

Close:856.387

Loading ...

BRIEF-Imugene Ltd Appoints Darren Keamy As CFO

Imricor Medical Systems Files Second Premarket Approval Module With US FDA; Shares Down 3%

MT Newswires Live

Invion Ltd-Proposed Issue of Securities - Ivx

THOMSON REUTERS

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary

THOMSON REUTERS

Imugene Ltd - Mike Tonroe Resigns as CFO

THOMSON REUTERS

Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso

THOMSON REUTERS

2 strong ASX 200 blue chip shares for your SMSF

Respiri Raises AU$4 Million via Placement

MT Newswires Live

Here are the top 10 ASX 200 shares today

BRIEF-Respiri Raises A$4M Through Placement & Proposed Name Change

Respiri to Deliver Care Management Services in Hawaii Under New Partnership; Shares Down 8%

MT Newswires Live

Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal

MT Newswires Live

Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why

BRIEF-Respiri Enters Partnership With Evolent Care Partners

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK7508/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":843.54193,"timestamp":1741582799994,"preClose":856.387,"halted":0,"volume":81305322,"delay":0,"changeRate":-0.014999,"change":-12.845093,"amount":116338255,"amplitude":0.016518,"prevYearClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":856.43976,"amplitude":0.016518,"preClose":856.387,"low":842.2942,"latestPrice":843.54193,"volume":81305322,"delay":0,"open":856.387,"prevYearClose":936.801,"prevWeekClose":856.387,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":869.45,"twentyDayClose":905.277,"sixtyDayClose":933.014,"secType":"PLATE","market":"AU","turnoverRate":0.002191,"marketCap":135233025924.25,"floatMarketCap":132069528109.75,"timestamp":1741582799994,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":17,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516693550","title":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693550?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:25","pubTimestamp":1741047942,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO March 4 (Reuters) - Imugene Ltd IMU.AX:APPOINTS DARREN KEAMY AS CFO AND COMPANY SECRETARYMIKE TONROE RESIGNS AS CFOFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2516553693","title":"Imricor Medical Systems Files Second Premarket Approval Module With US FDA; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516553693","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516553693?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:24","pubTimestamp":1741047884,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  submitted its second premarket approval module for US Food and Drug Administration  review, according to a Tuesday filing with the Australian bourse.The module covers design, manufacturing, and quality processes for seven products, and includes design controls, raw material receipt, inspection, storage, build procedures, process validation, part and device traceability, and quality management systems, the filing said.The company's NorthStar 3D mapping and guidance system will be submitted next under the 510 process.Shares fell nearly 3% in morning trade Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7503","BK7508","IMR.AU","BK7007"],"gpt_icon":0},{"id":"2516494660","title":"Invion Ltd-Proposed Issue of Securities - Ivx","url":"https://stock-news.laohu8.com/highlight/detail?id=2516494660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516494660?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:49","pubTimestamp":1741045786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUE9SJQN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVX.AU","BK7508","BK7096","BK7509"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["DXB.AU","BK7501","BK7067","DMX","BK7508","FSGS"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7067","CUV.AU","IMU.AU","BK7508","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2516661368","title":"Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661368?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2516661359","title":"Imugene Ltd - Mike Tonroe Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661359?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2516666705","title":"Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666705?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:33","pubTimestamp":1741037617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0YV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2516775657","title":"2 strong ASX 200 blue chip shares for your SMSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2516775657","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516775657?lang=en_us&edition=fundamental","pubTime":"2025-03-04 02:37","pubTimestamp":1741027020,"startTime":"0","endTime":"0","summary":"If you are on the hunt for new additions to your self-managed super fund (SMSF), then it could pay to listen to what analysts at Bell Potter are saying about the shares in this article. The broker has","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/04/2-strong-asx-200-blue-chip-shares-for-your-smsf/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["JHX.AU","CSL.AU","BK7511","BK7044","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2516508089","title":"Respiri Raises AU$4 Million via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516508089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516508089?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:05","pubTimestamp":1740985541,"startTime":"0","endTime":"0","summary":"Respiri  is set to raise AU$4 million via a share placement following the acquisition of the Orb Health business, according to a Monday filing with the Australian bourse.The placement consists of two tranches, the first tranche of AU$2.7 million will be issued on March 10 and the second tranche of AU$1.3 million will issued on June 5, the filing said.The shares will be issued under the company's existing placement capacity, with around 100 million shares to be issued at AU$0.04 per share, a discount of 16.7% from the company's last closing price on Feb.26.RSP also intends to change its name to Vitasora Health, upon receipt of approval from its shareholder at an Extraordinary General Meeting.Shares of the company rose past 4% at market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7508","BK7503","RSH.AU"],"gpt_icon":0},{"id":"2516626577","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516626577","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516626577?lang=en_us&edition=fundamental","pubTime":"2025-03-03 14:06","pubTimestamp":1740981980,"startTime":"0","endTime":"0","summary":"It was a very pleasant start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rather horrid week last week, investors seemed to come back from the weekend with a renewed s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/here-are-the-top-10-asx-200-shares-today-03-march-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7041","BK7030","BK7153","JLG.AU","BK7095","BK7083","BK7504","BOE.AU","BK7503","AD8.AU","BK7043","BK7073","BK7161","BK7126","QAN.AU","BK7508","KLS.AU","BK7507","PNV.AU","ILU.AU","BK7125","NXT.AU","MIN.AU","XJO.AU","BK7055","HVN.AU"],"gpt_icon":1},{"id":"2516571147","title":"BRIEF-Respiri Raises A$4M Through Placement & Proposed Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2516571147","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516571147?lang=en_us&edition=fundamental","pubTime":"2025-03-03 13:11","pubTimestamp":1740978663,"startTime":"0","endTime":"0","summary":"BRIEF-Respiri Raises A$4M Through Placement & Proposed Name ChangeMarch 3 (Reuters) - Respiri Ltd RSH.AX:RESPIRI RAISES $4M THROUGH PLACEMENT & PROPOSED NAME CHANGEISSUE PRICE OF A$0.04 PER NEW SHAREALL CURRENCIES IN  AUDFurther company coverage: RSH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUEWCBLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","RSH.AU","BK7508","BK7007"],"gpt_icon":0},{"id":"2516457803","title":"Respiri to Deliver Care Management Services in Hawaii Under New Partnership; Shares Down 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516457803","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516457803?lang=en_us&edition=fundamental","pubTime":"2025-03-03 11:05","pubTimestamp":1740971139,"startTime":"0","endTime":"0","summary":"Respiri  partnered with Evolent Care Partners and Hawaii Independent Physicians Association to provide care management services to Medicare beneficiary patients in Hawaii, according to a Monday filing with the Australian bourse.The company will initially focus on 1,800 Medicare Shared Savings Program patients, expecting to generate per-patient per-month reimbursement revenues of $100 to $200 for services rendered, the filing said.First patients' enrollment is expected in April, according to the filing.Shares were down 8% in afternoon trade on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7503","BK7508","RSH.AU"],"gpt_icon":0},{"id":"2516364524","title":"Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364524?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:43","pubTimestamp":1740966234,"startTime":"0","endTime":"0","summary":"Opthea  announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-nave patients.The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a \"statistically significant\" gain in best corrected visual acuity compared to ranibizumab alone.Opthea's shares rose almost 3% in recent trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OPT","BK7067","OPT.AU"],"gpt_icon":0},{"id":"2516574632","title":"Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2516574632","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516574632?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:10","pubTimestamp":1740964200,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is racing higher today. Again. Shares in the  S&P/ASX 300 Index  clinical-stage biotechnology company closed on Friday trading for $2.52. In earlier trade, shares were up 8.3% at $2.73 each. That saw the stock up an eye-popping 810% since this time last year. Or enough to turn an $8,000 investment into $72,800. In just 12 months. After some likely profit-taking, the Mesoblast share price is currently trading at $2.65, up 5.2%.  Here's what's grabbing ASX 200 investor interest today. Mesoblast share price benefits from its own success The ASX 200 biotech stock appears to be garnering additional tailwinds today generated by its own lengthy run higher. You see, with the Mesoblast share price having roared from 30 cents a share 12 months ago to $2.65 today, the company's market cap has surged to $3.4 billion. Why is that important?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/03/up-810-in-a-year-the-mesoblast-share-price-is-surging-again-on-monday-heres-why/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IOZ.AU","XKO.AU","BK7511","MESO","RIO.AU","BK7508","A200.AU","BK4139","BK7036","BK7507","BK7501","LTM.AU","BK7067","BK7095","MSB.AU"],"gpt_icon":0},{"id":"2516752965","title":"BRIEF-Respiri Enters Partnership With Evolent Care Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752965?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:04","pubTimestamp":1740963897,"startTime":"0","endTime":"0","summary":"BRIEF-Respiri Enters Partnership With Evolent Care PartnersMarch 3 (Reuters) - Respiri Ltd RSH.AX:ENTERS PARTNERSHIP WITH EVOLENT CARE PARTNERS' TO DELIVER CARE MANAGEMENT SERVICES IN HAWAIIFurther company coverage: RSH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL008:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSH.AU","BK7503","BK7007","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":11,"pageCount":5,"totalSize":174}]}}